DNA Script joins EuropaBio: Advancing Enzymatic DNA Synthesis Technology
NEWS RELEASE
Brussels, 25 October 2023 - EuropaBio is pleased to announce that DNA Script has joined the association as an Associate Member.
Based in Paris and founded in 2014, DNA Script is a company manufacturing de novo synthetic nucleic acids using an enzymatic technology. It aims to transform how molecular biology translates to human health, personalised medicine, and synthetic biology.
DNA Script was created to adapt DNA synthesis with enzymes. Its core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations resulted in the world’s first benchtop DNA printer powered by enzymatic technology. DNA Script’s vision is to empower researchers and life sciences to make biology truly programmable, democratise access to EDS technology, and accelerate the bio revolution. By enabling broad access to synthetic DNA printing, DNA Script aspires to drive new discoveries in research, personalised healthcare, therapeutics, diagnostics, and many other vital areas.
EuropaBio Director-General Dr. Claire Skentelbery said “We are thrilled to welcome DNA Script as an Associate Member of EuropaBio. Its pioneering work in enzymatic DNA synthesis technology aligns perfectly with our mission to advance biotechnology for the betterment of human health and the environment.”
DNA Script Senior Director Public Affairs Sophie Peresson said “We very much look forward to working with Europabio, especially at such an opportune and critical time when biotechnology has been identified as a critical sector for the EU.”